ResearcherLund UniversityActive in the last 2 years
Jakob Eberhard
Matched on ORCID iD 0000-0001-7597-9864; OpenAlex author ID A5016342783. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 10
2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: 3 papers · 2023: none · 2024: none · 2025: 1 paper
Papers 7
- Reliable on-treatment prognostication and target identification with a customized assay for circulating tumor DNA in patients with newly diagnosed pancreatic c… Co-author DOI 10.1038/s41598-025-22369-5↗
- PRR11 unveiled as a top candidate biomarker within the RBM3-regulated transcriptome in pancreatic cancer. Co-author DOI 10.1002/cjp2.238↗
- Integration of Specialized Palliative Care with Oncological Treatment in Patients with Advanced Pancreatic Cancer. Co-author DOI 10.1089/pancan.2022.0004↗
- Branching Copy-Number Evolution and Parallel Immune Profiles across the Regional Tumor Space of Resected Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-21-0986↗
- Second-line palliative chemotherapy, survival, and prognostic factors in patients with advanced pancreatic cancer. Co-author DOI 10.1080/0284186x.2021.1973680↗
- Translational study reveals a two-faced role of RBM3 in pancreatic cancer and suggests its potential value as a biomarker for improved patient stratification. Co-author DOI 10.18632/oncotarget.23486↗
- Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer. Last author DOI 10.3109/0284186x.2015.1075663↗
Closest collaborators
The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Karin Jirström · 5 shared papers, 2016–2025 · strength 0.66
- Paper Reliable on-treatment prognostication and target identification with a customized assay for circulating tumor DNA in pa… DOI 10.1038/s41598-025-22369-5↗
- Paper PRR11 unveiled as a top candidate biomarker within the RBM3-regulated transcriptome in pancreatic cancer. DOI 10.1002/cjp2.238↗
- Paper Branching Copy-Number Evolution and Parallel Immune Profiles across the Regional Tumor Space of Resected Pancreatic Can… DOI 10.1158/1541-7786.mcr-21-0986↗
- Sofie Olsson Hau · 3 shared papers, 2022–2025 · strength 0.52
- Paper Reliable on-treatment prognostication and target identification with a customized assay for circulating tumor DNA in pa… DOI 10.1038/s41598-025-22369-5↗
- Paper PRR11 unveiled as a top candidate biomarker within the RBM3-regulated transcriptome in pancreatic cancer. DOI 10.1002/cjp2.238↗
- Paper Branching Copy-Number Evolution and Parallel Immune Profiles across the Regional Tumor Space of Resected Pancreatic Can… DOI 10.1158/1541-7786.mcr-21-0986↗
- Jacob Elebro · 4 shared papers, 2016–2022 · strength 0.43
- Paper PRR11 unveiled as a top candidate biomarker within the RBM3-regulated transcriptome in pancreatic cancer. DOI 10.1002/cjp2.238↗
- Paper Branching Copy-Number Evolution and Parallel Immune Profiles across the Regional Tumor Space of Resected Pancreatic Can… DOI 10.1158/1541-7786.mcr-21-0986↗
- Paper Translational study reveals a two-faced role of RBM3 in pancreatic cancer and suggests its potential value as a biomark… DOI 10.18632/oncotarget.23486↗
- Mikael Segerlantz · 2 shared papers, 2021–2022 · strength 0.42
- Paper Integration of Specialized Palliative Care with Oncological Treatment in Patients with Advanced Pancreatic Cancer. DOI 10.1089/pancan.2022.0004↗
- Paper Second-line palliative chemotherapy, survival, and prognostic factors in patients with advanced pancreatic cancer. DOI 10.1080/0284186x.2021.1973680↗
- Anders Ekström · 2 shared papers, 2021–2022 · strength 0.42
- Paper Integration of Specialized Palliative Care with Oncological Treatment in Patients with Advanced Pancreatic Cancer. DOI 10.1089/pancan.2022.0004↗
- Paper Second-line palliative chemotherapy, survival, and prognostic factors in patients with advanced pancreatic cancer. DOI 10.1080/0284186x.2021.1973680↗
- Karin Leandersson · 2 shared papers, 2022–2025 · strength 0.37
- Paper Reliable on-treatment prognostication and target identification with a customized assay for circulating tumor DNA in pa… DOI 10.1038/s41598-025-22369-5↗
- Paper Branching Copy-Number Evolution and Parallel Immune Profiles across the Regional Tumor Space of Resected Pancreatic Can… DOI 10.1158/1541-7786.mcr-21-0986↗
- Alexandra Petersson · 2 shared papers, 2022–2025 · strength 0.37
- Paper Reliable on-treatment prognostication and target identification with a customized assay for circulating tumor DNA in pa… DOI 10.1038/s41598-025-22369-5↗
- Paper Branching Copy-Number Evolution and Parallel Immune Profiles across the Regional Tumor Space of Resected Pancreatic Can… DOI 10.1158/1541-7786.mcr-21-0986↗
- Maja Svensson · 1 shared paper, 2025 · strength 0.23
- Emelie Karnevi · 2 shared papers, 2018–2022 · strength 0.22
- Margareta Heby · 2 shared papers, 2016–2018 · strength 0.15
- Paper Translational study reveals a two-faced role of RBM3 in pancreatic cancer and suggests its potential value as a biomark… DOI 10.18632/oncotarget.23486↗
- Paper Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pan… DOI 10.3109/0284186x.2015.1075663↗
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.